408 related articles for article (PubMed ID: 14766246)
1. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
4. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
6. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
7. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
Chai Y; Wu W; Zhou C; Zhou J
Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
[TBL] [Abstract][Full Text] [Related]
8. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
9. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer.
Seo SS; Song YS; Kang DH; Park IA; Bang YJ; Kang SB; Lee HP
Gynecol Oncol; 2004 Mar; 92(3):927-35. PubMed ID: 14984962
[TBL] [Abstract][Full Text] [Related]
11. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
Solomon LA; Munkarah AR; Schimp VL; Arabi MH; Morris RT; Nassar H; Ali-Fehmi R
Gynecol Oncol; 2006 Jun; 101(3):385-9. PubMed ID: 16443262
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
13. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer.
Chan JK; Loizzi V; Magistris A; Lin F; Rutgers J; Osann K; Disaia PJ; Berman ML
Clin Cancer Res; 2004 Dec; 10(24):8538-43. PubMed ID: 15623636
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
15. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer.
Chan JK; Magistris A; Loizzi V; Lin F; Rutgers J; Osann K; DiSaia PJ; Samoszuk M
Gynecol Oncol; 2005 Oct; 99(1):20-5. PubMed ID: 16055178
[TBL] [Abstract][Full Text] [Related]
16. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
[TBL] [Abstract][Full Text] [Related]
17. Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis.
Castellvi J; Garcia A; de la Torre J; Hernandez J; Gil A; Xercavins J; Ramón y Cajal S
Hum Pathol; 2006 Jul; 37(7):883-9. PubMed ID: 16784989
[TBL] [Abstract][Full Text] [Related]
18. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.
Høgdall EV; Christensen L; Høgdall CK; Frederiksen K; Gayther S; Blaakaer J; Jacobs IJ; Kjaer SK
APMIS; 2008 May; 116(5):400-9. PubMed ID: 18452430
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
20. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]